Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

LianBio Approved to Launch Cardiomyopathy Therapy in Macau

publication date: May 12, 2023

Shanghai LianBio announced that Camzyos® (mavacamten), its therapy for obstructive hypertrophic cardiomyopathy (oHCM), has been approved to launch in Macau SAR. It is the first approval for LianBio, which was formed to bring innovative drugs to China. Last month, LianBio reported positive topline results from a China Phase III for mavacamten in patients with symptomatic oHCM. China’s NMPA will review the drug under Priority rules. In 2020, LianBio in-licensed China rights to the drug from MyoKardia in a $187.5 million agreement. More details....

Stock Symbol: (NSDQ: LIAN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital